Human Recombinant IL-2 (CHO-expressed)

Interleukin 2
Catalog #
78036_C
Interleukin 2
From: 76 USD

Overview

Interleukin 2 (IL-2) is a monomeric cytokine that was originally identified as a T cell growth factor (Gaffen & Liu). It binds to heterotrimeric receptors consisting of CD25, CD122, and CD132. Upon binding, it activates JAK3-, STAT5-, and AKT-dependent signaling pathways, which results in cellular proliferation and survival (Ma et al.). The majority of IL-2 is secreted by activated CD4+ and CD8+ T cells, although B cells and dendritic cells were found to produce IL-2 in small amounts. IL-2 downregulates immune responses to prevent autoimmunity during thymic development, influences the development of CD4+CD25+ regulatory T cells, and affects development of follicular helper T cells. IL-2 also controls inflammation by inhibiting Th17 differentiation (Banchereau et al.). High IL-2 levels in serum are associated with progression of scleroderma, rheumatoid arthritis, and gastric and non-small cell lung cancer, though no known disease can be directly attributed to the lack or excess of IL-2 (Gaffen & Liu). Human Recombinant IL-2 has a serine substitute for cysteine at position 126.
Subtype
Cytokines
Alternative Names
Aldesleukin, Interleukin-2, T cell growth factor, TCGF
Cell Type
Hematopoietic Stem and Progenitor Cells, NK Cells, T Cells, T Cells, CD4+, T Cells, CD8+
Species
Human
Area of Interest
Immunology, Stem Cell Biology
Molecular Weight
15.3 kDa
Purity
≥ 95%

Related Products

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
Human Recombinant IL-2 (CHO-expressed)
Catalog #
78036, 78036.1, 78036.2, 78036.3
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Human Recombinant IL-2 (CHO-expressed)
Catalog #
78036, 78036.1, 78036.2, 78036.3
Lot #
All
Language
English

Educational Materials(3)

Brochure
Tools For Your Immunology Research
Brochure
Cytokines, Chemokines and Growth Factors
Wallchart
Human Immune Cytokines

Data and Publications

Data

(A) The biological activity of Human Recombinant IL-2 (CHO-expressed) was tested by its ability to promote the proliferation of CTLL-2 cells. Cell proliferation was measured using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which cell proliferation is at 50% of maximum. The EC50 in the above example is 1.2 ng/mL.
(B) 2 μg of Human Recombinant IL-2 (CHO-expressed) was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant IL-2 (CHO-expressed) has a predicted molecular mass of 15.3 kDa.

Publications (1)

Nature medicine 2018 OCT Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. M. Cerezo et al.

Abstract

Preventing the immune escape of tumor cells by blocking inhibitory checkpoints, such as the interaction between programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) receptor, is a powerful anticancer approach. However, many patients do not respond to checkpoint blockade. Tumor PD-L1 expression is a potential efficacy biomarker, but the complex mechanisms underlying its regulation are not completely understood. Here, we show that the eukaryotic translation initiation complex, eIF4F, which binds the 5' cap of mRNAs, regulates the surface expression of interferon-$\gamma$-induced PD-L1 on cancer cells by regulating translation of the mRNA encoding the signal transducer and activator of transcription 1 (STAT1) transcription factor. eIF4F complex formation correlates with response to immunotherapy in human melanoma. Pharmacological inhibition of eIF4A, the RNA helicase component of eIF4F, elicits powerful antitumor immune-mediated effects via PD-L1 downregulation. Thus, eIF4A inhibitors, in development as anticancer drugs, may also act as cancer immunotherapies.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.